Elutia Inc. Stock Price, News & Analysis

Elutia (Nasdaq: ELUT) announced that Dr. Randy Mills, President and CEO, will present at the LD Micro Main Event XIX in San Diego on Tuesday, October 21, 2025 at 1:00 p.m. PT (4:00 p.m. ET).

A live webcast will be available and Elutia management will hold 1x1 investor meetings. Institutional investors may schedule meetings via an LD Micro representative or by emailing IR@elutia.com.

Elutia (Nasdaq: ELUT) announced on October 10, 2025 the appointment of Guido J. Neels to its Board of Directors; he will also join the Board's audit committee. Mr. Neels brings >40 years of global medical technology leadership, including roles as Operating Partner at EW Healthcare Partners and former Chief Operating Officer of Guidant. In conjunction with his appointment, W. Matthew Zuga and Maybelle Jordan stepped down from the Board. Management framed the hire as supporting Elutia's strategic transformation after the recent EluPro divestiture and to advance its drug‑eluting biomatrix technology into breast reconstruction.

Elutia (NASDAQ:ELUT) has completed the sale of its BioEnvelope business to Boston Scientific Corporation (NYSE:BSX) for $88 million in cash. The sale includes the EluPro™ and CanGaroo® bioenvelopes product lines.

The company will now focus on developing NXT-41x, a drug-eluting biomatrix targeting breast reconstruction infections post-mastectomy. The product addresses a $1.5 billion U.S. market opportunity, with planned market launch in first half of 2027. Currently, one in three breast reconstruction patients face serious complications, with biologics representing 65% of implant-based costs.

Elutia (Nasdaq: ELUT) has published significant clinical and preclinical data demonstrating the effectiveness of their biologic envelopes for cardiac implantable electronic devices (CIEDs). The HEAL study revealed that patients with ECM envelopes experienced 43% lower overall procedural difficulty, including 46% easier generator mobilization and 41% easier lead mobilization during reoperations.

The research also showed complete eradication of bacterial pathogens, including MRSA, with sustained local antibiotic concentrations for up to two weeks. The company's drug-eluting biomatrix technology combines regenerative ECM with broad-spectrum antibiotics to address both infection control and tissue remodeling, with potential applications in higher-risk procedures like breast reconstruction.

Elutia (Nasdaq: ELUT) has announced the sale of its BioEnvelope business, including EluPro™ and CanGaroo® bioenvelopes, to Boston Scientific Corporation (NYSE: BSX) for $88 million in cash. The transaction is expected to close in Q4 2025.

The deal represents a strategic move that validates Elutia's drug-eluting biologics platform and provides non-dilutive funding for the development of NXT-41, targeting the $1.5 billion U.S. breast reconstruction market. The proceeds will enable Elutia to eliminate outstanding debt, address litigation from its previous Orthobiologics business, and reduce burn rate while focusing on advancing its SimpliDerm franchise.

Elutia (Nasdaq: ELUT) has been selected to showcase its EluPro™ Antibiotic-Eluting BioEnvelope at the Vizient Innovative Technology Exchange on September 17, 2025, in Las Vegas. EluPro is the first and only FDA-cleared antibiotic-eluting bioenvelope designed for cardiac implantable electronic devices and neurostimulators.

The technology combines a natural biologic scaffold with time-release antibiotics to promote tissue regeneration while providing antimicrobial protection at the surgical site. The product aims to address post-surgical complications including infection, migration, and erosion while enhancing procedural efficiency.

Elutia (Nasdaq: ELUT), a drug-eluting biomatrix technologies company, has announced its participation in three upcoming investor conferences in New York this September.

The company's leadership, including CEO Dr. Randy Mills and CFO Matt Ferguson, will attend the Cantor Global Healthcare Conference (Sept. 4), the H.C. Wainwright Global Investment Conference (Sept. 10), and the Lake Street Capital Markets Best Ideas Growth Conference (Sept. 11). The first two events will feature fireside chats and presentations, while the Lake Street conference will focus on one-on-one meetings.

Elutia (NASDAQ: ELUT) reported strong Q2 2025 results, driven by its flagship EluPro™ antibiotic bioenvelope. EluPro's Q2 revenue surged 49% sequentially, with BioEnvelope revenue reaching $3.5 million, up 33% year-over-year. The company has achieved significant market penetration with over 160 VAC-approved centers and strategic partnerships with Boston Scientific.

Total Q2 2025 revenue was $6.3 million, with gross margin improving to 48.8%. The company reported a net loss of $9.6 million. Elutia is advancing its pipeline with NXT-41, a next-generation drug-eluting biomatrix for breast reconstruction, targeting FDA clearance in 2H26. The company expects BioEnvelope sales to approach a $20 million annualized run rate by year-end.

Elutia (Nasdaq: ELUT), a drug-eluting biomatrix technologies company, has scheduled its second quarter 2025 financial results release for Thursday, August 14, 2025, after market close.

The company will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day. Management will be available to discuss the results, with both domestic and international dial-in numbers provided for investor participation.